Empagliflozin for heart failure with preserved ejection fraction and dialysis
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older
- You have end-stage kidney disease and have been on stable dialysis for at least 6 months
- You have been diagnosed with heart failure with preserved ejection fraction using a specific scoring tool
- You are not pregnant
- You do not have severe heart failure symptoms (NYHA class IV) or any hospitalization for heart failure in the past month
- You do not have a recent acute infection (urinary, genital) or serious artery disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
This trial tests whether empagliflozin improves kidney health and the function of the belly’s dialysis membrane in people with end-stage kidney disease who do peritoneal dialysis. It may help by changing how well the peritoneal dialysis system works and how the kidneys perform over time.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
This study tests whether a medication called empagliflozin (a diabetes drug) can improve heart function in older adults with high blood pressure and obesity who are at risk for heart failure but do not have it yet. You would take the pill daily and have heart ultrasounds to check your heart's health.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.